• "Biotech where science and spirit meet..."
Skip to content

{ Category Archives: } Biotech Stocks To Watch

Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study

Osaka, Japan, and Chicago October 22, 2019 –Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and COUR Pharmaceutical Development Company, Inc. (“COUR”) today announced that Takeda has acquired an exclusive global license to develop and commercialize the investigational medicine CNP-101/TAK-101, an immune modifying nanoparticle containing gliadin proteins. Based on COUR’s antigen specific immune tolerance platform, TAK-101 is…

Biotech GSK gives Clover adjuvant for vaccine against ‘indispensable’ COVID-19 protein

GlaxoSmithKline has struck a deal to provide its pandemic adjuvant to Clover Biopharmaceuticals for use in a COVID-19 vaccine candidate. Clover is one of a clutch of organizations working to tackle COVID-19 by targeting a protein the novel coronavirus needs to enter host cells. China’s Clover, which is based 600 miles west of the focal point of…

11 drugs likely to become blockbusters

The 11 drugs Clarivate expects to become blockbusters by 2024: Rimegepant (Biohaven Pharmaceutical) — designed to treat migraines. OMG-157 (Novartis) — designed to treat multiple sclerosis. Ozanimod (Celgene) — designed to treat multiple sclerosis. Vadadustat (Akebia Therapeutics/Mitsubishi Tanabe Pharma America/ Otsuka Pharmaceutical) — designed to treat anemia caused by chronic kidney disease. Valrox (BioMarin Pharmaceutical)…

Oligomerix to Present at BIO CEO & Investor Conference, TAU2020 Global Conference

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s disease (AD) and related neurodegenerative disorders, announces that the company will be presenting at two conferences this month. James Moe, Ph.D., MBA, President and CEO of Oligomerix, will provide a company overview at the 2020 BIO CEO &…

BrainStorm CEO to Provide Company Update at the BIO CEO & Investor Conference

NEW YORK, Feb. 04, 2020 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits, CEO and President, will provide an update of the Company’s ALS and MS trials and company growth strategy at The BIO CEO & Investor Conference, being held…

BrainStorm Receives Notice of Intention to Grant Additional EU patent for NurOwn®

NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the European Patent Office (EPO) has communicated its intention to grant a European patent titled ‘Methods of Generating Mesenchymal Stem Cells which secrete Neurotrophic Factors’. Allowed claims cover the method for manufacturing…

Bausch Health Companies (BHC) Receives a Buy from Barclays

In a report issued on January 24, Balaji Prasad from Barclays maintained a Buy rating on Bausch Health Companies (BHC – Research Report), with a price target of $33.00. The company’s shares closed last Monday at $28.40. According to TipRanks.com, Prasad is a 4-star analyst with an average return of 16.6% and a 70.0% success rate. Prasad covers the Healthcare sector, focusing on stocks…

GLOBAL HIRUDIN PRODUCTS MARKET 2020 – THE MEDICINES COMPANY, TEVA PHARMACEUTICAL INDUSTRIES LTD, PFIZER, INC

The Global Hirudin Products Market report Interpretes the complete details covering Executive summary, Scope of the report, Research Methodology, Introduction, Market landscape, Market segmentation by type, Segmentation by application, Latest Geographical segmentation, Decision framework Drivers and challenges Market trends, Vendor landscape, Key vendor analysis based on production region, major players, and product type which will provide a…

The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 billion

– The Medicines Company to be acquired by Novartis AG for $85 per share in cash, representing 45% premium to its unaffected share price and a 57% premium to its unaffected one-week average price – Inclisiran, The Medicines Company’s investigational, innovative, potent twice-annual therapy to lower LDL cholesterol, has potential to transform treatment of cardiovascular…

Marijuana producer Organigram stock soars 30% as sales double

Organigram Holdings Inc. stock soared 30% during extended trading Tuesday, as the Canadian weed company reported fiscal first-quarter revenue that jumped two-fold, beating Wall Street estimates. Net revenue rose to C$25.2 million ($19.3 million) from C$12.4 million a year ago, which beat the consensus estimate of C$21 million, according to analysts polled by FactSet. The…